CAMP4 Therapeutics (CAMP) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed CAMP4 Therapeutics (CAMP) over the past year, gaining 93.4% versus a gain of 30.7%. Prelude Therapeutics is the larger company by market cap ($258.6 million vs $237.8 million), about 1.1 times the size, while CAMP4 Therapeutics is growing revenue faster (+436.5% vs +73.4%). Prelude Therapeutics converts more of its revenue into profit, with a net margin of -819.6% versus -2298.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | PRLD |
|---|---|---|
| Share price | $3.79 | $3.23 |
| Market cap | $237.84M | $258.63M |
| 1-day change | -5.25% | -0.77% |
| YTD return | -38.17% | +11.38% |
| 1-year return | +30.69% | +93.41% |
| 5-year return | — | -76.93% |
| EPS (TTM) | $-2.11 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.50M | $12.14M |
| Revenue growth (YoY) | +436.50% | +73.43% |
| Net income (latest FY) | $-80.40M | $-99.50M |
| Operating margin | -1502.43% | -861.33% |
| Net margin | -2298.54% | -819.59% |
| 52-week high | $7.75 | $6.83 |
| 52-week low | $2.90 | $1.30 |
| Distance from 52-week high | -51.10% | -52.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +169.66% | +172.45% |
| Average volume | 238.88K | 432.74K |
| Shares outstanding | 62.75M | 65.34M |
| Employees | 48 | 79 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed CAMP by 62.7 percentage points over the past year.
- Prelude Therapeutics is more profitable, keeping -819.6 cents of every revenue dollar as net income versus -2298.5 cents for CAMP4 Therapeutics.
- CAMP4 Therapeutics grew revenue faster in its latest fiscal year (+436.50% vs +73.43%).
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
CAMP vs PRLD FAQ
Which is bigger, CAMP4 Therapeutics or Prelude Therapeutics?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $258.63M compared with $237.84M for CAMP4 Therapeutics (CAMP).
Which stock has performed better over the past year, CAMP or PRLD?
PRLD returned +93.41% over the past 12 months, compared with +30.69% for CAMP (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.